Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Proteomic biomarkers for survival in systemic sclerosis-associated pulmonary hypertension.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • Contributors:
      Santé Ingénierie Biologie Saint-Etienne (SAINBIOSE); Centre Ingénierie et Santé (CIS-ENSMSE); École des Mines de Saint-Étienne (Mines Saint-Étienne MSE); Institut Mines-Télécom Paris (IMT)-Institut Mines-Télécom Paris (IMT)-École des Mines de Saint-Étienne (Mines Saint-Étienne MSE); Institut Mines-Télécom Paris (IMT)-Institut Mines-Télécom Paris (IMT)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM); Hôpital Bicêtre AP-HP, Le Kremlin-Bicêtre; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Hypertension pulmonaire : physiopathologie et innovation thérapeutique (HPPIT); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay; Centre d'Investigation Clinique - Epidémiologie Clinique CHU Saint-Etienne (CIC-EC 1408); Centre Hospitalier Universitaire de Saint-Etienne CHU Saint-Etienne (CHU ST-E)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM); Centre Hospitalier Universitaire de Saint-Etienne CHU Saint-Etienne (CHU ST-E); Université Jean Monnet - Saint-Étienne (UJM); Lille Inflammation Research International Center - U 995 (LIRIC); Institut Pasteur de Lille; Pasteur Network (Réseau International des Instituts Pasteur)-Pasteur Network (Réseau International des Instituts Pasteur)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille); Centre Hospitalier Régional Universitaire de Tours (CHRU Tours); Hôpital Avicenne AP-HP; Hypoxie et Poumon : pneumopathologies fibrosantes, modulations ventilatoires et circulatoires (H&P - U1272 Inserm); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Sorbonne Paris Nord-UFR Santé Médecine et Biologie Humaine (UFR SMBH); Université Sorbonne Paris Nord-Université Sorbonne Paris Nord; Hôpital Nord CHU - APHM; Hôpital Européen Georges Pompidou APHP (HEGP); Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO); Hôpital Louis Pradel CHU - HCL; Hospices Civils de Lyon (HCL); Centre national de référence des maladies pulmonaires rares Lyon (CRMPM); Centre Hospitalier Universitaire CHU Grenoble (CHUGA); Université Claude Bernard Lyon 1 (UCBL); Université de Lyon; Infections Virales et Pathologie Comparée - UMR 754 (IVPC); École Pratique des Hautes Études (EPHE); Université Paris Sciences et Lettres (PSL)-Université Paris Sciences et Lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL); Université de Lyon-Université de Lyon-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)
    • بيانات النشر:
      CCSD
      BioMed Central
    • الموضوع:
      2023
    • Collection:
      EPHE (Ecole pratique des hautes études, Paris): HAL
    • نبذة مختصرة :
      International audience ; BackgroundInterstitial lung disease (ILD) and pulmonary hypertension (PH) represent the major causes of mortality in systemic sclerosis (SSc). Patients with systemic sclerosis and combined PH and ILD (SSc-PH-ILD) generally have a poor prognosis. Predictors of survival and of potential benefit of treatment are lacking in patients with SSc-PH-ILD.ObjectiveTo identify specific plasma protein expression patterns associated with survival in patients with SSc-PH-ILD.Materials and methodsPost-hoc analysis of a prospective multicenter French study in patients with PH-ILD. An untargeted proteomic analysis using mass spectrometry was performed to identify plasma protein changes associated with long-term overall survival in patients with SSc-PH-ILD.ResultsThirty two patients were included in the analysis, of whom 13 died during follow-up (median survival: 76.5 months). At baseline, survivors had less severe hemodynamic impairment [pulmonary vascular resistance of 4.4 Wood Units (IQR 3–5.2) vs. 6.2 Wood Units (IQR 4.2–10.7)] and higher carbon monoxide diffusing capacity [median 39% (IQR 35–44%) vs. 25% (IQR 22–30.5%)], than the 13 patients who died. Seven proteins, associated with haemostasis and fibrosis, were differentially expressed according to patients’ survival. In the survivor group, two proteins were increased (ADAMTS13, SERPIND1) and five were decreased (PTGDS, OLFM1, C7, IGFBP7, FBN1) compared to the non-survivor groups.ConclusionThe prognosis of SSc-PH-ILD patients is poor. This proteomic approach found 7 plasma proteins (involved in haemostasis and fibrosis pathways) associated with survival. These potential biomarkers may be good candidates to prognostic enrichment.
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/37936223; PUBMED: 37936223
    • الرقم المعرف:
      10.1186/s12931-023-02578-0
    • الدخول الالكتروني :
      https://hal.univ-lille.fr/hal-04495514
      https://hal.univ-lille.fr/hal-04495514v1/document
      https://hal.univ-lille.fr/hal-04495514v1/file/s12931-023-02578-0.pdf
      https://doi.org/10.1186/s12931-023-02578-0
    • Rights:
      http://creativecommons.org/licenses/by/ ; info:eu-repo/semantics/OpenAccess
    • الرقم المعرف:
      edsbas.8EFACB87